References
- Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531–540.
- Denning DW, Ribaud P, Milpied N, . Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.
- Lee DG, Kim SH, Kim SY, . Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011; 26: 220–252.
- Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–637.
- Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998; 20: 243–247.
- Pascual A, Calandra T, Bolay S, . Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–211.
- De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.
- Product information. VFend (voriconazole). New York: Pfizer, November 2006.
- Segal BH, Herbrecht R, Stevens DA, . Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674–683.
- Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010; 9: 125–137.
- Trifilio S, Ortiz R, Pennick G, . Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.
- Trifilio SM, Yarnold PR, Scheetz MH, . Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother 2009; 53: 1793–1796.
- Trifilio S, Pennick G, Pi J, . Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532–1535.
- Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927–933.
- US Food and Drug Administration. Briefing document for voriconazole (oral and intravenous formulations). FDA Antiviral Drugs Advisory Committee; 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf.
- Scholz I, Oberwittler H, Riedel KD, . Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68: 906–915.
- Ueda K, Nannya Y, Kumano K, . Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592–599.